On April 29, CMS issued its final rule for Medicare Part D for contract year 2023. Our NCPA policy team has studied the rule carefully and has created this analysis for members. NCPA has advocated tirelessly for many years for Medicare Part D pharmacy DIR fee reform. While this final rule is not perfect, it is a huge step forward to bring much needed transparency to Part D drug pricing and pharmacy reimbursement. NCPA will continue the fight against anticompetitive plan sponsor/PBM activity that harms both Part D beneficiaries and small business pharmacies. This final rule is the latest chapter of years of NCPA and member pharmacies advocating for Part D changes that will make pharmacy reimbursement more transparent and predictable.
NCPA
